Here we summarized novel Chimeric antigen receptor T-cell immunotherapy(CAR-T)based on the immune material aspect.Young healthy donor T cells,stem cell-like memory T cells,human induced pluripotent stem cells and umbilical cord blood T cells are all potential candidates to enhance CAR-T cell therapy depending on their anti-tumor efficacy.Besides,due to less restricted major histocom-patibility complex(MHC)mismatch effect,viral specific T cells,γδT cells,invariant natural killer T cells and macrophages also become idealized T cell sources in terms of Universal CAR-T(UCAR-T)cell thera-peutics.In addition,studies demonstrated that more balanced CD4+/CD8+T cell ratio and eliminating monocytes during leukapheresis have a positive influence on CAR-T cell functioning,whereas T cells with higher exhaustion markers expression hampers anti-tumor ability of CAR-T cells after infusion.To avoid application of such T cells or mitigate the impact using immune checkpoint inhibitors is of great impor-tance.
维普
万方数据
